Cramer’s lightning round: Enterprise Products Partners is a winner
Illumina: “Illumina is great, not just because [CNBC contributor Dr. Scott Gottlieb] is on the board. They’ve got unbelievable technology, and I love the diagnostic business. Buy Illumina.”
Atai Life Sciences NV: “This is one that’s down so low that’s it’s now just a terrific spec, frankly. You don’t know, it’s a roll of the dice, but it’s spec and I would not sell it down here. $6, I’d be a buyer.”
Riskified: “No, no. It IPO’d in July. That’s just an invitation to be [crushed like shares of Peloton have recently been]. If you want that security, buy NortonLifeLock. We own it for the [CNBC Investing Club] and it’s closing on a very big deal. I think that’s the one to be in.”
Doximity: “Well, I was right for awhile. Now I’ve been wrong. I think doctors love it. Ask your doctor. They’re going to swear by it. This is not Teladoc by the way, which has been completely [crushed like shares of Peloton have recently been], if not toasted. I think that DOCS is good, but like I said, I’ve been wrong. I think it’s an indispensable product, and they make money, which to me says good growth.”
Enterprise Products Partners: “I like EPD. You’ve got a good dividend. You’ve got growing volumes now. You’ve got solid management, yields 7.8% [at roughly $22 per share]. That is a winner. I wish [co-CEO] Jim Teague would come on. It would be great.”
SoFi Technologies: “Well maybe what happened … is it should never have been up there. And by the way, somebody did an unbelievable secondary and got the hell out of that thing at a really good price. I’d actually like to know more about the secondary than I would about the stock.”
Sign up now for the CNBC Investing Club to follow Jim Cramer’s every move in the market.